Companies Dominating the Hematopoietic Stem Cells Transplantation Landscape
- Lonza Group Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Escape Therapeutics, Inc.
- Regen BioPharma, Inc.
- ThermoGenesis Holdings, Inc.
- CSG-BIO Company, Inc. (CellSave)
- CBR Systems, Inc.
- Pluristem Inc.
- Global Cord Blood Corporation
- ViaCord, LLC
- Cynata Therapeutics Limited
Browse Key Market Insights with Data Illustration:
In the News
- Lonza Group announced to increase the number of human stem cells it offers by supplying big batch sizes of CD34+ hematopoietic stem cells from human cord blood to expand cohorts for greater capacity and easier HLA-matched model development.
- Regen BioPharma, Inc. Announced the introduction of a novel immunotherapy approach using chimeric antigen receptor (CAR) natural killer (NK), macrophage (M), and T cells (T) to overcome the challenges associated with T cell fatigue in existing strategies and enable these cell therapies to successfully target solid tumors.